KYRNF (Kyorin Pharmaceutical Co) Non Operating Income: $0.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KYRNF Kyorin Pharmaceutical Co Ltd KYRNF
69 GF Score
Price $10.31
GF Value $13.83
! 7 Warning Signs
View Full Analysis

What is Kyorin Pharmaceutical Co Non Operating Income?

Kyorin Pharmaceutical Co KYRNF 69 Non Operating Income is $0.0 Mil as of Mar. 2026. GuruFocus rates KYRNF with a GF Score™ of 69/100 and a GF Value™ of $13.83. The stock has 7 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Kyorin Pharmaceutical Co's Non Operating Income for the three months ended in Mar. 2026 was $0.0 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $0.0 Mil.

Kyorin Pharmaceutical Co Non Operating Income Related Terms

Kyorin Pharmaceutical Co Non Operating Income Historical Data

* Premium members only.

The historical data trend for Kyorin Pharmaceutical Co's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyorin Pharmaceutical Co Non Operating Income Chart

Kyorin Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kyorin Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
KYRNF
69GF Score
Kyorin Pharmaceutical Co Ltd KYRNF
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyorin Pharmaceutical Co Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $0.0 Mil mean?
Kyorin Pharmaceutical Co (KYRNF) has a Non Operating Income of $0.0 Mil as of Mar. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Kyorin Pharmaceutical Co and its competitors.
Is Kyorin Pharmaceutical Co's Non Operating Income too high?
Kyorin Pharmaceutical Co's current Non Operating Income is $0.0 Mil. Overall, Kyorin Pharmaceutical Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Kyorin Pharmaceutical Co's Non Operating Income compare to ZTS?
Kyorin Pharmaceutical Co's Non Operating Income of $0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Drug Manufacturers company?
A good Non Operating Income depends on the Drug Manufacturers industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Kyorin Pharmaceutical Co and its competitors. Kyorin Pharmaceutical Co's current Non Operating Income is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyorin Pharmaceutical Co stock overvalued right now?
Kyorin Pharmaceutical Co (KYRNF) has a current Non Operating Income of $0.0 Mil. The stock's GF Value™ is $13.83, compared to a current price of $10.31 — trading 25.5% below its estimated fair value. The current Non Operating Income is $0.0 Mil. Kyorin Pharmaceutical Co's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Kyorin Pharmaceutical Co (KYRNF), the current Non Operating Income is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyorin Pharmaceutical Co (KYRNF) Overvalued in 2026?

Based on GuruFocus' analysis, Kyorin Pharmaceutical Co stock appears to be undervalued. The current stock price of $10.31 is trading 25.5% below its estimated GF Value™ of $13.83.

Key valuation signals for KYRNF:

  • Non Operating Income: $0.0 Mil
  • GF Value™: $13.83 vs. price of $10.31 (25.5% below fair value)
  • GF Score™: 69/100 with 7 warning signs

No single metric tells the full story. See the KYRNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kyorin Pharmaceutical Co Business Description

Other Exchanges 4569:Japan
Address 6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
69GF Score

Get the complete analysis for KYRNF

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.31
Price
$13.83
GF Value